Merck, SCC294, OVSAHO Human High-grade Serous Ovarian Cancer Cell Line

General description
Ovarian cancer (OC) remains one of the leading causes of cancer-related deaths in women worldwide, with the all-stage 5-year relative survival rate across the globe of only 30 40% (Reid 2017). High-grade serous carcinoma (HGSOC) accounts for 70% of all
Application
Each vial contains ≥ 1X10⁶ viable cells.Cells are tested negative for infectious diseases by a Human Essential CLEAR panel by Charles River Animal Diagnostic Services.Cells are verified to be of human origin and negative for inter-species contamination from rat, mouse, Chinese hamster, Golden Syrian hamster, and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.Cells are negative for mycoplasma contamination.Each lot of cells is genotyped by STR analysis to verify the unique identity of the cell line.
Ovarian cancer (OC) remains one of the leading causes of cancer-related deaths in women worldwide, with the all-stage 5-year relative survival rate across the globe of only 30–40%.1 High-grade serous carcinoma (HGSOC) accounts for 70% of all ovarian cancers and is also one of the more lethal forms of ovarian cancer due to its rapid growth and early spread to other organs in the peritoneal cavity.2 Ovarian cancer cell lines have historically been the most frequently used tumor models to prescreen experimental anticancer agents in vitro and to select specific histologic subtypes of epithelial OC for further exploration of these agents. Xenograft models relying on implantation of established EOC cell lines have also been extensively used in ovarian cancer research and are important experimental platforms for preclinical drug development.3Source OVSAHO is a permanent human ovarian carcinoma cell line established from the abdominal metastasis of a serous papillary adenocarcinoma patient.4 In addition to being a reproducible in vitro HGSOC source, OVSAHO cells have been shown to be amenable to intraperitoneal and subcutaneous4 as well as orthotopic5 heterotransplantation in nude and even immune-competent mice. OVSAHO ranked second among 47 ovarian cancer cell lines listed in the Cancer Cell Line Encyclopedia and The Cancer Genome Atlas in having the highest genetic similarity to ovarian tumors.6 References1. Reid BM, Permuth JB, Sellers TA. 2017. Epidemiology of ovarian cancer: a review. Cancer Biol. Med. 14, 9–32.2. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. 2019. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci. 20(4): 9523. Konstantinopoulos PA, Matulonis UA. 2013. Current Status and Evolution of Preclinical Drug Development. Models of Epithelial Ovarian Cancer. Frontiers in Oncology 3(1): 296. 4. Yanagibashi T, Gorai I, Nakazawa T, Miyagi E, Hirahara F, Kitamura H, Minaguchi H. 1997. Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br. J. Cancer 76: 829-835.5. Berger J, Beck TL, Mital P, Elishaev E, Sukhwani M, Oesterreich S, Vlad A, Krivak TC, Kelley III JL, Orwig K. 2015. A novel orthotopic mouse model of epithelial ovarian carcinoma demonstrating progression from early stage disease to carcinomatosis in both immune-competent and immune-deficient models Gynecologic Oncology Volume 137, Supplement 1, April 2015, Page 132 (Poster Abstract).6. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. 2014. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4:2126-2126.
Features and Benefits
OVSAHO is a permanent human ovarian carcinoma cell line established from the abdominal metastasis of a serous papillary adenocarcinoma patient
Preparation Note
Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
Other Notes
Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact [email protected].
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.